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Abstract

Nicotine has gained the attention of the medical community due to its insidious
addictive mechanisms which lead to chronic consumption. The multitude of compounds
derived from tobacco smoke have local and systemic negative impacts, resulting in a large
number of smoking-related pathologies. The present review offers insights into nicotine
addiction physiopathology, as well as social and medical implications, with emphasis on
its correlation with Advanced Glycation End Products (AGEs). Therapeutic strategies and
new approaches to nicotine assessment and cessation treatment are discussed, noting that
such strategies could take into account the possibility of slow and gradual nicotine release
from a device attached to a prosthetic piece, based on salivary nicotine-concentration
feedback. This approach could offer real-time and home-based self-therapy monitoring by
the physician and the patient for follow-up and improve long-term cessation treatment
success- Graphical abstract.
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✓ Smoking addiction has strong pharmacological, psycho-social, and media support.
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✓ The development of a double-effect salivary biosensor could represent a useful approach
in nicotine addiction therapy.
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Introduction

Materials and Methods

Nicotine, with the molecular formula C10H14N2 and
IUPAC name 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine, is
a natural alkaloid found in the tobacco plant, Nicotiana
tabacum (1). It has been grown in Native America since
1400 BCE and then brought to Europe via King Philip the
2nd of Spain, through his Spanish Chronicler Hernández de
Boncalo. The name “cigar” is derived from “cicadas,” the
insects that caused plague in the tobacco cultures (2, 3).
Over time, nicotine has been used in trading, as a
ceremonial tool, as a manner of socializing, for pleasure or
relaxation, and for its therapeutic potential in systemic
diseases. Nicotine’s hazard consists in the fact that it is
being used both as an addictive substance and as a
medication in smoking cessation therapies. The purpose of
the present paper is to provide an update regarding the
molecular and pathogenic mechanisms of smoking
addiction, with emphasis on its correlation with Advanced
Glycation End Products (AGEs). We also discuss smoking
cessation strategies and include reference to an innovative
approach that associates nicotine addiction therapy with a
biosensor inserted in a prosthetic piece, used both as a realtime analyzer and as a treatment option.

This paper is a narrative review of studies involving
molecular and pathogenic mechanisms of nicotine
addiction, nicotine metabolism, medical consequences,
smoke-derived AGEs, cessation treatment options and
alternatives, and innovative approaches in nicotine
replacement therapy.
The authors used “PUBMED” and MeSH to gather
published papers on the above-mentioned aspects. The
following keyword associations were used: “nicotine
addiction”, “nicotine” AND “smoking”, “nicotine” AND
“pathogenic mechanism”, “nicotine” AND “genetic
determinism”, “nicotine” AND “metabolism”, “smoking”
OR “nicotine” AND “AGEs”, “smoking” OR “nicotine”
AND “disease”, “smoking cessation” AND “Nicotine
Replacement Therapy (NRT)” OR “saliva”, “smoking
cessation” AND “salivary biosensor”.
Inclusion criteria were free full-text articles in English,
Spanish, or Portuguese. Human and animal model studies
were both included. Only papers from 2000 and onward
were included.
There were no exclusion criteria concerning the study
design.

Graphical abstract
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Figure 1. Review extraction - data methodology chart

Results
1. Nicotine addiction
1.1 Nicotine and smoking
Tobacco
combustion
produces
carcinogenic
compounds such as benzene, formaldehyde, benzapyrene,
carbon monoxide, and cyanide asphyxiants, acrolein,
polonium, as well as tobacco-derived pro-inflammatory
advanced glycation end-products (AGEs) (4). Lewis et al.
identified three types of smoking: active smoking, passive
smoking or second hand smoke (SHS), and third hand
smoke (THS), referring to the oxidized compounds that
turn into carcinogens, along with tobacco-derived
nitrosamines, polycyclic aromatic hydrocarbons (PAH),
deposited on objects and surfaces humans come in contact
with, which can also be inhaled, absorbed through the skin,
or ingested (4). THS, also named Residual tobacco smoke
or Aged tobacco smoke, has been measured using liquid or
gas chromatography, along with mass spectrometry and
has a 6-month lifetime in indoor spaces and on surfaces.
These residuals induce DNA alteration, cytotoxicity,
increased exhaled Nitric Oxide (NO), liver metabolism
dysregulation, and thrombosis.
DiFranza and co-workers elaborated a sequence of
wanting-craving-needing smoking pattern in chronic
consumers (5). The authors stated that in the first stage of
nicotine dependence, the early symptom is to want a
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cigarette, the second stage is an intense craving for a
cigarette, which disturbs daily activity and thoughts, and
the third stage is needing, an independent intense demand.
The period of latency after smoking a cigarette is followed
by an active symptomatic stage with manifestations such
as anxiety, anger, restlessness, insomnia, difficulty in
focusing, and increased appetite. These researchers also
found that nicotine dependence is suggested by the
shortening of the latency time (6). Cerebral stimuli are
driven towards the increase in tobacco input, to maintain
balance, and the latency period thus decreases in time,
because nicotine’s half-life is approximately two hours.
Hormones have a modulating effect on nicotine via
dopamine, and one hormone, estrogen, is known to
influence time perception and cognition. Specifically, time
can be perceived as either faster or slower, an important
aspect regarding the perceived time period between two
smoked cigarettes. Cognition may be affected in terms of
decision making and delay discounting (7). Females
metabolize nicotine and cotinine faster than men, and their
metabolism is influenced by hormonal therapy, with oral
contraceptives slowing tobacco smoke-derived compound
disintegration (8, 9). A study conducted on active smokers,
aged 18 to 65 years, with a history of at least 10
cigarettes/day for at least 6 months, demonstrated that men
overestimated the abstinence period compared to women
(10) (Figure 2).
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Figure 2. Nicotine addiction
1.2 Pathogenic molecular mechanisms of nicotine
addiction

either cholinergic or GABA neuron sub-populations of
mHb-IPN, which increase the parasympathetic activity and

Nicotine enters blood circulation and binds to pre- or
postsynaptic acetylcholine receptors (nAChR); these
receptors are responsible for acetylcholine (Ach),
dopamine (DA), serotonin, and norepinephrine release. In
the brain, the most expressed receptors are α4β2 and α7
nAChR (11). When ventral tegmental area (VTA)
DAα4β2 nAChR is stimulated by nicotine, VTA cells enter

lead to IPN stimulation as a final result, increasing
withdrawal symptoms.

a phasic condition, with increased DA release in the

a 8.02 dissociation constant that splits nicotine into two
halves, one ionized and one non-ionized, the latter being
the absorbed form (14). It takes only 15 seconds for
nicotine to pass the lipophilic blood brain barrier and reach
50% of its concentration in the cerebral areas (15). Nicotine
input is regulated by the consumer, by his smoking habits
(frequency and depth of inhaling), the wellness of the

nucleus accumbens (NAc) and prefrontal cortex, and
through this mechanism, nicotine mediates relaxing and
pleasure effects, considered to be the key point in nicotine
addiction (12). Nicotine also stimulates μ-opioid
receptors (MOR) from gamma-Aminobutyric acid
(GABA) in the VTA area, decreasing GABA secretion and
increasing DA release from NAC (11). Molas et al.
demonstrated that the interpeduncular nucleus (IPN) axis
from the medial habenula (mHb) regulates acute nicotine
activity, due to its high nAChRs concentration (13). IPN
controls fear and anxiety-related reflexes, which are among
the nicotine withdrawal effects and are also nAChR
mediated. In chronic consumers, nAChRs are regulated by

1.3 Nicotine metabolism
The oral mucosa absorption

of

nicotine

and

consequently its pulmonary alveoli and blood flow are
influenced by its concentration and free-form. The
alkalinity of saliva enhances nicotine absorption, which has

pulmonary system, and the environmental quality. After
absorption, nicotine is highly concentrated in the hepatic
tissue, kidney, lung, spleen, and slightest concentration in
fat tissue, whereas for cotinine, the highest concentration is
found in liver (16).
Cytochrome P450 2A6/5 (CYP2A6/5), which is part of
CYP 450 enzyme family, is the main enzyme responsible
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for nicotine oxidation and it can induce ROS and oxidative
stress; at the hepatic level, nicotine is C-oxidized and
inactivated to cotinine and cotinine to 3′-hydroxycotinine
(3HC) (16). The assessment of the correlations between
CYP2A6 and renal nicotine clearance has revealed two
types of smokers: slow nicotine metabolizers and fast
nicotine metabolizers; fast metabolizers have a higher risk
of developing addiction and a lower rate of success in
smoking cessation (17). P450 2A6 and P450 2A13
enzymes also catalyze nicotine methyl oxidation, resulting
in nornicotine, N’-nitrosonornicotine, a pulmonaryspecific carcinogenic compound (18). Often, tobacco and
alcohol are consumed together and they have a mutual
metabolic influence. Cytochrome P450 2E1 is increased in
chronic alcohol consumption, and the simultaneous
consumption of the two substances promotes lipid
peroxidation, alcoholic fatty liver, and alcoholic cirrhosis
(19). Alcohol consumption increases fast nicotine removal
due to the increased activity of the liver CYP2A6 (20, 21).
CYP2A5 influences the nicotine and cotinine
bioavailability, expressed by the fact that nicotine’s
concentration is higher in the brain compared to cotinine,
because of the slower liver cotinine metabolism and its

difficulty crossing the brain barrier (22). Nicotine is
actively transported by the renal cells and because of its
basic condition, its excretion rate is influenced by urine
pH, compared to cotinine which is influenced only by the
urinary flow (23) (Figure 3). By means of oxidative
stress, nicotine promotes renal impairment and tubular
injury, which are expressed more in young renal tissues
(24). NAChR are present in mesangial cells, proximal
tubular cells, and podocytes. Nicotine downregulates
nephrin constitution and increases the pro-apoptotic
podocyte Bax enzyme and ROS production in a dosedependent manner, enhancing the progression of chronic
renal disease (25). Regarding nicotine and cotinine
metabolism, factors influencing the compound
elimination include: grapefruit juice- inhibits hepatic
enzymes; menthol increases cotinine’s half-life and the
metabolism of nicotine; women have a higher tobaccoderived product metabolic rate than men, which is
accelerated in the presence of oral contraceptives, agerelated delayed clearance; and general diseases that
include renal failure, alcoholic liver disease, hepatitis,
associated disease inductor and inhibitor medication; and
smoking habits (16).

Figure 3. Nicotine metabolism and the pathogenic molecular mechanisms of nicotine addiction
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1.4 Genetic determinism of nicotine addiction
Genome-wide association studies (GWAS) have
assessed single nucleotide polymorphism (SNP) genes
associated with smoking initiation. Results have shown
that the following proteins are involved in smoking
behavior and addiction: glutamate receptor subunits
(GRIN2A, GRIN2B, GRIK2, and GRM8), cell adhesion
molecules (CDH23), neurotrophic receptor tyrosine kinase
(NTRK2), and the growth factor receptor-bound protein 14
(GRB14) (26). Jensen et al. investigated the relationship
between smoking and the SNP in protocadherin (PCDH), a
transmembrane protein present in neural synapses, in 3600
patients (27). They administered nicotine intravenously
after an overnight abstinence and their results showed that
patients with PCDH SNP responded fast and effectively to
nicotine infusion. GWAS also found an association
between NACHR subunits (CHRNA3-4-5-6, CHRNB2-34), dopamine b-hydroxylase (DBH), Flavin-containing
monooxygenase (FMO), and nicotine dependence.
Smokers with a reduced CYP2A6 allele activity
(CYP2A6*2, *4, *9, *12) have a slower nicotine metabolic
rate (a higher plasma nicotine concentration) and a
decreased hepatic enzyme activity, while CYP2A6*1B
smokers have a higher metabolic rate (8).
1.5 Genetic determinism in smoking cessation
A systematic review of 46 papers on the geneticmedication interaction reported that several genes were
involved in nicotine addiction, smoking withdrawal, and
medication efficacy: CHRNA5-A3-B4, CYP2A6, DBH,
CHRNA4, COMT, DRD2, DRD4 and CYP2B6 (28). The
SNP in CYP450 2A6, the enzyme that inactivates nicotine
to cotinine, is known to have a direct influence on the
number of smoked cigarettes, smoking behavior, and the
efficacy of varenicline and bupropion treatments,
especially in fast nicotine metabolizers compared to slow
metabolizers. Researchers have also found the genetic
implication for the dopamine pathway, more precisely
dopamine COMT enzyme in addiction mechanism (28).
2. Social context and medical implications
Smoking habits are influenced by a number of factors
(29). Agaku et al. collected information from
Eurobarometer 345 and analyzed the determining smoking
factors and the marketing and design elements (30). The
initiation of smoking and the brand’s choice were enhanced
by the pleasant smell and taste of tobacco, its packaging,
price, and specific flavors. The analysis further showed that
attractiveness was increased by the length, diameter, and
additives such as menthol or cinnamon. Cigarette
marketing uses terms such as “light”, “organic”, “silver”,
which have an appealing effect on buyers, and make them

seem less harmful. The World Health Organization’s
Directives regulate tobacco products’ design, flavor, and
marketing, including statements which would influence the
consumers to choose a specific tobacco brand.
Chronic nicotine consumption leads to tobacco
dependence, which pragmatically occurs when the
individual “desires” a cigar or cigarette. The degree of
dependence is commonly diagnosed with the Fagerström
test, which classifies smoking psychiatric disorders,
anxiety and depression (31). The World Health
Organization (WHO) states that over a million deaths are
caused by smoking each year, of which 600,000 are not
active smokers, and alerts the population that the number
of consumers is increasing and the initiation age decreases
(32). The cigar/cigarette smoke and its products induce a
chronic inflammatory status (33), a continuous increase in
mortality due to pulmonary obstructive disease, cardiac
disease, oral cavity and lung cancer, along with other
cofactors (34, 35). Carcinogenic, irritating, and
asphyxiating nicotine and other smoke compounds are
absorbed by means of the pH, so that the high-soluble
substances are absorbed in the upper airways, whereas less
soluble substances are absorbed in the pulmonary cells
(36). Nicotine’s cytotoxic effect on oral cavity structures
has been tested on human periodontal stem cells (37).
Different nicotine concentrations induced autophagic
activity, decreased periodontal stem cells viability, and
altered the periodontium cell turnover, which, when taken
into account, induces and aggravates the periodontal
disease. Oral hygiene and exhaled carbon monoxide were
assessed on a group of 65 subjects (50 smokers, 15 nonsmokers) (38). Plaque, gingival calculus index, and CO
were recorded. The degree of nicotine dependence was
evaluated using the Fageström test. The study showed that
Fagerström scores were directly related to daily tooth brush
frequency and gingival index. Smoking was positively
correlated with bad oral hygiene as indicated by gingival,
plaque, and calculus indices.
3. The correlation between nicotine and Advanced
Glycation End Products (AGEs)
Advanced glycation end products (AGEs) are final
products of Maillard reaction; in a medical context, AGEs
have been associated with the enhanced production of
reactive oxygen species (ROS), and the subsequent
generation of oxidative or carbonyl stress, thus leading to
an inflammatory response. AGEs encompass a large group
of products, of which pentosidine, carboxymethyllysine
(CML), glyoxal-lysine dimer (GOLD), and methylglyoxal
(MG) have been intensely investigated (39). Based on their
source, two classes of AGEs are known: the endogenous
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AGEs (formed in oxidative stress conditions,
hyperglycemia) and exogenous AGEs: dietary AGEs
(dAGEs). Moreover, AGEs can be produced by UV
(ultraviolet) radiation, nicotine and cigarette smoke, and
microwaves and ultrasounds (40). Smoking AGEs are
formed in several hours and bind to connective tissue
collagen fibers, leading to increased tissue hardness.
AGEs mainly act through an immunoglobulin surface
receptor (RAGE) mechanism and induce chronic
inflammation. Nicotine and nornicotine are enhancing
factors for the tissular expression of AGEs. Sanders et al.
has shown that gingival epithelial cells exposed to
cigarette smoke extract (CSE) exhibited increased RAGE
and cytokine mediated inflammatory response, including
Ras and nuclear factor kappa B (NF- B) pathways. This
research group used semi-synthetic glycosaminoglycan
ethers (SAGEs) and demonstrated the inhibitory effect on
AGEs due to the decreased effect on cytokine production
in cells stimulated by CSE (41). Chapman et al. evaluated
the effect of SAGE in oral squamous cell carcinoma
(OSCC) cells exposed to CSE in different concentrations
(0.05%, 0.1%, 0.2%, and 0.5%) (42). Smoke extract
increased AGEs expression and OSCC cell proliferation.
The removal of etiological CSE and SAGE treatment
decreased the inflammatory response (the production of
matrix metalloproteinases 2, 9, 14) and induced OSCC
cell downregulation (Figure 4).
An in vitro study regarding the effect of CSE on rat
alveolar epithelial cell lines showed that CSE activated
RAGE; Ras is involved in cell growth and differentiation;
and NF- B is related to carcinogenesis and cancer
progression (43). Marinucci et al. investigated nicotine,
methylglyoxal (MG), a component of cigarette smoke,
and AGEs effect on the differentiation and proliferation
of human osteoblastic cells, with the focus on
osteoporosis (44). They also pretreated osteoblasts with
Tiron- an antioxidative and AG- scavenger for MG and
its derivatives (MG-H1). Nicotine induced a dose- and
time-dependent increase in RAGE and hydrogen peroxide
(H2O2). Tiron reduced nicotine induced-apoptosis and
the AG pretreatment showed the involvement of MG-H1
in RAGE overexpression and cellular apoptosis. The
accumulation of tobacco-sourced AGEs in the skin can be
assessed by using the autofluorescence (SAF) technique.
Waateringe et al. used the AGE Reader to assess skin
AGEs derived from active and secondhand cigarette
smoke exposure, along with smoking withdrawal, in
healthy individuals and diabetic patients (45). High SAF
levels were correlated with diabetic active smokers and
SAF intensity was correlated with the hours of cigarette
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smoke exposure. In contrast, cigarette cessation led to
SAF decrease. The authors stated that for a former
smoker, it takes approximately 15 years to reach the same
SAF levels as a non-smoker.
4. Treatment strategy in nicotine addiction
In the National Socialist Germany, smoking was
considered to be un-Aryan, and thus smoking cessation
was politically driven. However, the efforts were not
effective, because of the stressful living conditions and
because cigarettes were used as postwar commercial goods
(46). After establishing the direct relationship between
cigarette smoke and lung cancer, surveys (47) and research
studies regarding smoking and its effects on human
physical and mental health were initiated. The most widely
used and effective methods in smoking cessation were
nicotine patches, bupropion, and varenicline FDA
approved medication, sometimes in conjunction with
cognitive/active therapy. Varenicline is a partial antagonist
which binds to nicotine acetylcholine (ACh) receptors and
inhibits the activation of the ACh receptor by nicotine,
leading to the lack of satisfaction while smoking (48).
Varenicline has a high affinity for a4ß2 nicotinic receptors,
blocking the addictive effect of nicotine; this medication
has the role of increasing dopamine in the cerebral
rewarding areas usually occupied by nicotine (49). A study
on 213 subjects compared the effectiveness of pre-quit
patches, varenicline (2 weeks before/10 weeks after
smoking cessation), and classical patches (50). The
pretreatment reduced smoking satisfaction and thus led to
a decrease in the number of smoked cigarettes. A more
invasive study investigated Nicotine Replacement Therapy
(NRT) using high dose nicotine patches (21-84 mg/day) for
smoking cessation, without interrupting conventional
smoking (51). Researchers found a reduction in pleasure
and the number of smoked cigarettes and reported no
relapse during the post therapeutic 4 weeks. The results
were attributed to the combined effect of high nicotine
dose: a nicotine patch pre-load bound to ACo receptors,
which led to an unpleasant sensation while inhaling and a
secondary side effect of a nicotine overload causing mild
nausea or vomiting (51). Other widely used NRT methods
are nicotine gum, nicotine inhaler, nicotine nasal spray,
where the nicotine inhaler provides up to 4 mg of nicotine,
which alone is not enough for a current smoker attempting
to quit. The author’s analysis showed that combining
nicotine patches with the inhaler increases the success rate
by two times. Caldwell stated that for achieving the
pleasant feeling, nicotine must pass through the pulmonary
route, and the association of a metered dose inhaler with
nicotine patches is a successful therapeutic approach (52).
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The spray and the inhaler’s particularity is the fact that their
deposition is mainly in the upper airways, while the inferior
pulmonary structures are spared, which represents a
positive feature especially in pulmonary obstructive
diseased chronic consumers (53). Active nicotine spray
associated with patches showed a prolonged period of
rebound compared to patches only (54, 55). The effect of
the sublingual nicotine tablet was compared to transdermal
patches, associated with moderate psychological
counseling (56).
In a mice model study, Saravia et al. investigated the
correlation between nicotine withdrawal and microglial
activation in prefrontal cortex and hippocampus, and the
effect of cannabidiol in redressing the cognitive damage
induced by cessation (57). Inflammatory proteins TNF-α,
IL-1ß, IL-10, and IFN increased in hippocampus and
prefrontal cortex stratum pyramidal on the 4th day after
nicotine withdrawal, while cannabidiol post-treatment
normalized TNF-α and IL-1ß levels. The authors suggested
that nicotine withdrawal syndrome altered neurogenesis by
enhancing the expression of inflammatory proteins, while
cannabinoids had a protective effect on cognition
impairment. In the same contextual area, Johnson et al.
investigated the implication of psilocybin in nicotine
withdrawal, the abstinence time, or the reduction in the
number of smoked cigarettes in a survey on 358 subjects
(58). The authors stated that the 5-HT2A 5-HT1A could
exert a psychedelic and endorphin-serotonin releasing
effect. Most of the subjects reported a decrease in the
number of smoked cigarettes or longer periods of
abstinence after the psychedelic experience. The delayed
psilocybin effect could alleviate several withdrawal
symptoms involving anxiety and craving, and could also
exert a parasympathomimetic effect. A meta-analysis by
Klinsophon et al. performed on 19 studies focusing on the
effect of physical activity on smoking cessation did not
reach clear conclusions due to the controversies regarding
ß-endorphins release after physical exercise (59).
However, the results showed that aerobic and resistance
exercises improved the patient’s mood, whereas yoga and
similar breathing and relaxing exercises led to stress
reduction, thus suggesting that parasympathetic stimuli had
a positive effect on smoking cessation.
Cigarette/cigar smoke’s first contact is with the oral
cavity’s structures. The negative effect of smoking on the
oral mucosa, periodontium, and bone quality and quantity
is undisputed, due to the nicotine’s toxic metabolites and
chronic inflammatory local response. Tobacco-induced
local pathology comprises dental caries, tobacco stains,
halitosis, hairy tongue, stomatitis, premalignant or

malignant lesions (60). The American Dental Association
(ADA) has suggested that dentists have the opportunity of
helping addicts in cessation therapy by using the 5-A
strategy: Ask, Advise, Assess, Assist, Arrange follow-up
(61). They can intervene positively because of the multiple
visits of the patient to the dental clinic for a direct control
of the oral and systemic health outcome. The dentist can
make patients aware of their oral health condition which
may be affected by smoking, especially periodontal
diseases, and the importance of cessation and the absence
of relapse in preserving dental treatment outcomes and
systemic conditions as well (62).
Due to the technological era and the heavy use of
smartphones, smoking cessation applications were
considered a positive approach to improving cessation
therapy results and a long-term abstinence period,
especially in adolescents and young adults. The medical
theory, the epidemiological data, the psychotherapeutic
aspects, and the user’s needs were involved in developing
theses apps (63, 64). The apps permit the patient to keep a
diary of the symptoms associated with quitting, the
quantification of the achievements the addict accumulates
during the therapy and especially after, and the online
psychotherapeutic characteristics (65). The interactive
nature of these applications showed increased patient
compliance after NRT therapy, with potential value for
such programs either as complementary or as a sequence in
smoking cessation programs (66).
4.1. Electronic cigarettes (ECs) – a healthier alternative?
ECs originally emerged as a healthier alternative to
conventional smoking. ECs contain tobacco specific
ingredients and flavors and include the following
components: a vaporizer with a heating mechanism, a
cartridge and a battery. The higher the voltage, the greater
the production of vapors and carcinogenic compounds
(67). EC-liquids include nicotine, propylene glycol (PG),
vegetable glycerin (VG), and flavors. DeVito et al. found
that PG/VG ratio influenced the nicotine input and the
concentration of toxic compounds (68). UK Health
Ministry asserted that EC vapors contain 95% fewer
noxious products than regular cigarette smoke (69). EC
vapors also contain nitrosamines, alkaloids, and turpentine
(used either as a solvent or as a scent for a pleasant
fragrance). Löhler and Wollenberg investigated the
differences between classic and electronic cigarettes and
their influence on adolescents’ and adults’ behavior. Their
results showed that most of the adult consumers had chosen
to adopt ECs due to their lower negative biological effects,
or as a way to reduce and quit smoking; another reason was
the possibility of smoking in restricted areas. In contrast,
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adolescent consumers considered ECs the initial stage,
preceding conventional smoking; the risk of changing the
ECs for conventional smoking seemed to be correlated
with the social, economic and educational status (70).
4.2. Old habits die hard - perspectives?
Nicotine addiction has a multifactorial etiology, from
genetic determinants to the context of social acceptance.
Daily stress has an obvious impact on the frequency and
quantity of nicotine use. Several studies have described the
mechanisms of the three stages of nicotine addiction, from
the wanting level (self-control) to the craving level in
which the receptors and the autonomic nervous system take
control. Cigarette consumers seem to ignore the
progressive multisystem alterations induced by the
metabolism of nicotine and smoke components
(carcinogens, AGEs-MG, asphyxiants, proinflammators,
irritants). Moreover, it is well known that second-hand and
third-hand smoke induce negative delayed effects in nonsmokers. The ECs are error-inducers for their users,
especially due to the design and the lack of smoke
elimination. Nicotine addiction is insidious and tricks
patients by an apparent self-control on cigarette input.
Clinical studies investigating several single or associated
cessation therapies have demonstrated that bupropion,
varenicline, and nicotine patches had increased efficacy,
and could be combined with physical/psychical therapy.
However, there are no studies on long-term follow-up. It is
not known when the relapse key moment occurs and
especially why many people who had given up smoking
eventually return to their unhealthy habit. There is no
certain quantity of nicotine or number of smoked cigarettes
which make a person become an addict. Further
investigations are needed to clarify the neural and
psychical factors that cause nicotine addiction and, most
importantly, the relapse mechanisms.

Discussions
Biosensors, nicotine assessment and NRT
In biofluids, biomarkers can be used to evaluate the
exposure, accumulation of nicotine, and cigarette smoke
byproducts, such as aromatic amines, polycyclic aromatic
hydrocarbons, acrylamide, benzene, and crotonaldehyde,
as well as the efficacy of cessation therapy (71). The
assessment was performed using different techniques:
liquid chromatography and immunochromatography, in
which cotinine is gold labeled nanoparticles combined with
an image sensor to quantify the signal of the bounded
product (72). Cotinine was mainly chosen as a tobacco
biomarker because of the differences between the half-life

204

of the two substances, 2 hours for nicotine and
approximately 20 hours for cotinine. The accumulation of
nicotine and cotinine in deciduous teeth was assessed using
gas chromatography/bmass spectrometry (GC/MS) and
liquid chromatography (LC)- tandem mass spectrometry
(MS/MS) to monitor tobacco exposure and the cumulative
effect of nicotine. To evaluate the efficacy of the cessation
therapy, nicotine and cotinine can be analyzed in biological
fluids such as saliva and urine. Salivary mouth swab (Oral
Fluid Device) cotinine tests were shown to give accurate
results of tobacco exposure, in both conventional cigarettes
and ECs, even in the case of delayed analysis of the
samples (73). It was shown that the concentration of
nicotine is higher in unstimulated saliva, and cotinine’s
concentration in stimulated saliva, because of the
differences in the salivary pH and tobacco’s ionized and
non-ionized metabolites (74). Synthetic receptors,
molecularly imprinted polymers bound to nicotine and
immobilized to quartz crystal and analyzed using quartz
crystal microbalance-dissipation (QCM-D) sensor, use the
viscoelastic properties of the investigated substances (75).
Researchers developed the molecularly imprinted
polymer-carbon nanotube sensor either for the
electrochemical heat-transfer-resistance based cotinine
detection or for quantification by using the electrical
resistance to the substance (76, 77).
Thus, numerous techniques are available for detecting
and quantifying nicotine and its metabolites as markers of
exposure or for evaluating and monitoring the cessation
treatment. There are various treatment approaches,
including pharmaceutic nicotine antagonists, NRT using
patches, gum, inhalers, sprays, drops, combined with
psychotherapy and newly introduced phone applications.
The majority of treatment methods use an oral
administration route due to the rapid absorption of nicotine
through the mucosa in the blood flow. One important
negative aspect is the compliance of the patient, because
the substances are mainly home self-medications. One
patient might underdose, which results in withdrawal
symptoms and a higher risk of relapse, or overdose, which
is not an effective step for ending the habit. To the best of
our knowledge, there is no intraoral device to provide
real-time nicotine or cotinine levels. Such a device should
be personalized, obtained through the interdisciplinary
relation between the dentist and the technician or the
orthodontist (78), and adapted to the anatomical
characteristics of the patient’s oral cavity. It could be
represented by a prosthetic piece, for example, a mouth
guard made from a biocompatible material in which a
small-dimensioned biosensor can be attached (79). For
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accurate results, the miniaturized device should be
capable of acquiring the essential information, measuring
the nicotine level in saliva by processing the received
data, and transmitting the results remotely, either wired
or mobile. The biosensor would assess real-time salivary
smoking biomarkers. For a lightweight, easy-handling
device, the power supply should be wireless and small.
Various battery dimensions and power are available for
medical applications that have low-power consumption 2uW at 1.2V, so the battery would be active for 6-7
months. Small sized wireless batteries (2 square
millimeters) can provide energy from active radio waves
(80). Engineers have developed a 3D holographic
lithography with a 2D photolithography micro battery,

less than 2 inches in dimension, which includes a highenergy material—tin—providing a long-life battery (81).
A significant challenge in miniaturizing the device lies in
the transmission step, in which an antenna is needed, a
component which is difficult or impossible to be
miniaturize. Due to the high-frequency of the smartphone
use by consumers, the results could be transferred by
using an analogue-to-digital convertor, connected by
Bluetooth to a phone application (82).
In this manner, the user of the device would know
when a new nicotine dose is scheduled, without regard to
his own thought processes or clinical symptomatology.
The above described nicotine investigation assays are
summarized in Table 1.

Table 1. Saliva, nicotine assessment and biosensors

would allow a real-time adjusted cure dosage as part of the
therapy. This could lead to a possible home-based therapy
in which both the attending physician and the patient could
have access to the evidence and treatment evolution.

A useful and innovative approach would be for the
nicotine’s biosensor prosthetic device to present an alert
system, which activates the release of a nicotine dose from
a reservoir into the oral cavity where it will be easily
absorbed. The dentist could play an important role in
monitoring, counseling the patient, and ensuring
maintenance of the device. The information provided by
the biosensor could be transmitted to the doctor’s
computing device. The approach would provide a valid,
accurate, real-time, and non-invasive evaluation of
nicotine use. Its non-invasive properties, combined with
NRT, could offer an attractive strategy for both the patient
and the physician. Saliva-stimulating slow and gradual
nicotine release from a prosthetic device active biosensor

Conclusions
Nicotine has drawn researchers’ attention after the
findings regarding the correlation between smoking and
pulmonary and other diseases. Smoking addiction has
strong pharmacological, psycho-social, and media support.
Evidence has shown that cigarette/cigar smoke and its
products simultaneously induce and aggravate multiple
pathologies, beginning with direct contact with the oral
mucosa and the upper respiratory airways, to tumoral
disease and addictive behavior. Smoking cessation
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strategies have a success rate strongly dependent on the
patient’s compliance. The development of a double-effect
salivary biosensor could represent a useful approach in
nicotine addiction therapy, both in the real-time monitoring
of nicotine levels and in precise nicotine dose
administration. This approach represents an innovative and
appealing approach in NRT. Future studies would need to
demonstrate the device’s efficacy and the patient’s
compliance to such device treatment options.
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